Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
Moodys
Federal Trade Commission
US Army
Fuji

Generated: September 24, 2019

DrugPatentWatch Database Preview

Patent: 7,993,638

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,993,638
Title:Cancer treatment combining lymphodepleting agent with CTLs and cytokines
Abstract: In a cancer treatment combining cell therapy with chemotherapy, autologous CD8.sup.+ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblative but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon-.alpha.-2b stimulatory cytokines.
Inventor(s): Cai; Zeling (San Diego, CA), Moriarty; Ann (Poway, CA), Peterson; Per A. (Rancho Santa Fe, CA), Richards; Jon M. (Glenview, IL)
Assignee: Janssen Pharmaceutica NV (BE)
Application Number:12/281,197
Patent Claims:see list of patent claims

Details for Patent 7,993,638

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Eisai Inc ONTAK denileukin diftitox VIAL 103767 001 1999-02-05   Try a Free Trial Janssen Pharmaceutica NV (BE) 2026-03-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Teva
AstraZeneca
Julphar
Harvard Business School
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.